Health care system delay and heart failure in patients with ST-segment elevation myocardial infarction treated with
Christian Juhl Terkelsen1, Lisette Okkels Jensen, Hans-Henrik Tilsted
1Aarhus University Hospital, Aarhus, Denmark.
Annals of Internal Medicine
|September 21, 2011
Summary
Shorter system delays for ST-segment elevation myocardial infarction (STEMI) patients receiving primary percutaneous coronary intervention (PPCI) are linked to reduced risks of congestive heart failure (CHF) readmissions. This finding highlights the importance of timely reperfusion therapy for STEMI survivors.
Area of Science:
- Cardiology
- Public Health
Background:
- System delay in reperfusion therapy for ST-segment elevation myocardial infarction (STEMI) is linked to mortality.
- Limited data exist on the risk of congestive heart failure (CHF) among STEMI survivors experiencing system delays.
Purpose of the Study:
- To investigate the association between system delay and the risk of readmissions or outpatient contacts due to CHF.
- To evaluate this association in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
Main Methods:
- A historical follow-up study utilizing population-based medical registries in Western Denmark.
- Analysis of 7952 STEMI patients treated with PPCI within 12 hours of symptom onset, with system delays of 6 hours or less.
- Competing-risk regression analysis was used to determine the cumulative incidence of CHF readmissions/contacts, with death as a competing risk.
Main Results:
- Increasing system delay correlated with higher long-term risks for CHF readmissions or outpatient contacts.
- Patients with delays of 181 to 360 minutes had a 14.1% risk, compared to 10.1% for delays of 60 minutes or less (P < 0.001).
- System delay was identified as an independent predictor of CHF readmissions/contacts (adjusted hazard ratio per hour increase: 1.10).
Conclusions:
- Shorter system delays to PPCI in STEMI patients are associated with a reduced risk of subsequent CHF readmissions or outpatient contacts.
- Timely reperfusion therapy is crucial for improving long-term outcomes and reducing CHF-related healthcare utilization in STEMI survivors.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...